Synthesis, cytotoxicity, DNA interaction and topoisomerase II inhibition properties of tetrahydropyrrolo[3,4-a]carbazole-1,3-dione and tetrahydropyrido-[3,2-b]pyrrolo[3,4-g]indole derivatives

被引:22
作者
Joseph, B
Facompré, M
Da Costa, H
Routier, S
Mérour, JY
Colson, P
Houssier, C
Bailly, C
机构
[1] IRCL, Ctr Oscar Lambret, INSERM U 524, F-59045 Lille, France
[2] IRCL, Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France
[3] Univ Orleans, UMR CNRS 6005, Inst Chim Organ & Analyt, F-45067 Orleans 2, France
[4] Univ Liege, Lab Chim Macromol & Chim Phys, B-4000 Liege, Belgium
关键词
D O I
10.1016/S0968-0896(01)00026-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Three tetrahydropyrrolo[3,4-a]carbazole-1,3-diones (6-8) and two tetrahydropyrido[3,2-b]pyrrolo[3,3,4-g]indole,1,3-diones (11-12) have been synthesized. Their interaction with DNA was probed by absorption and thermal melting studies. Compounds 8 and 12 both equipped with a hydroxyethyl-aminoethyl side-chain demonstrated higher affinities for poly(dA-dT)(2) than compounds 6, 7 and 11 bearing a dimethylaminoethyl side-chain. Circular and electric linear dichroism measurements showed that all five drugs behave as typical DNA intercalating agents. A. plasmid cleavage assay was used to evaluate the capacity of the drugs to inhibit human topoisomerase II. Compounds 8 and 12 which bind strongly to DNA were found to stabilize DNA-topoisomerase II covalent complexes but their topoisomerase II inhibitory properties do not correlate with their cytotoxic potential. Compounds 6 and 7 are essentially inactive whereas compounds 8, 11 and 12 exhibit a high toxicity to P388 murine leukemia cells and provoke a marked accumulation in the G2/M phase of the cell cycle. These compounds form a new class of DNA-targeted antitumor agents. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1533 / 1541
页数:9
相关论文
共 32 条
[1]  
ARAKAWA H, 1995, CANCER RES, V55, P1316
[2]  
BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1
[3]   Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities [J].
Bailly, C ;
Qu, XG ;
Chaires, JB ;
Colson, P ;
Houssier, C ;
Ohkubo, M ;
Nishimura, S ;
Yoshinari, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (15) :2927-2935
[4]   DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin [J].
Bailly, C ;
Riou, JF ;
Colson, P ;
Houssier, C ;
RodriguesPereira, E ;
Prudhomme, M .
BIOCHEMISTRY, 1997, 36 (13) :3917-3929
[5]   Topoisomerase I poisons and suppressors as anticancer drugs [J].
Bailly, C .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (01) :39-58
[6]   Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition [J].
Bailly, C ;
Qu, XG ;
Graves, DE ;
Prudhomme, M ;
Chaires, JB .
CHEMISTRY & BIOLOGY, 1999, 6 (05) :277-286
[7]  
Brown RFC, 1997, LIEBIGS ANN-RECL, P1931
[8]  
Byl JAW, 1999, BIOCHEMISTRY-US, V38, P15573
[9]  
CAPRANICO G, 1995, CURRENT PHARM DESIGN, V1, P1
[10]   Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA [J].
Colson, P ;
Bailly, C ;
Houssier, C .
BIOPHYSICAL CHEMISTRY, 1996, 58 (1-2) :125-140